Y-mAbs Therapeutics (NASDAQ:YMAB) Announces Earnings Results

Y-mAbs Therapeutics (NASDAQ:YMAB) released its earnings results on Monday. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08), Zacks reports. The business had revenue of $22.80 million during the quarter, compared to analysts’ expectations of $23.09 million. Y-mAbs Therapeutics had a negative return on equity of 21.40% and a negative net margin of 25.64%. During the same period last year, the business earned ($0.14) earnings per share. Y-mAbs Therapeutics updated its FY 2024 guidance to EPS.

Y-mAbs Therapeutics Stock Up 7.5 %

NASDAQ YMAB traded up $0.81 on Wednesday, reaching $11.63. The stock had a trading volume of 140,977 shares, compared to its average volume of 358,274. The stock has a fifty day moving average price of $11.86 and a two-hundred day moving average price of $13.73. Y-mAbs Therapeutics has a 12-month low of $4.69 and a 12-month high of $20.90. The firm has a market capitalization of $510.36 million, a price-to-earnings ratio of -23.86 and a beta of 0.66.

Analyst Ratings Changes

YMAB has been the subject of several analyst reports. Canaccord Genuity Group upgraded Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday. Morgan Stanley lowered their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $22.00 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday. Wedbush reaffirmed an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday. Finally, Truist Financial initiated coverage on Y-mAbs Therapeutics in a report on Friday, June 28th. They set a “buy” rating and a $21.00 price target for the company. Two research analysts have rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.29.

Insider Transactions at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 35,000 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $12.03, for a total transaction of $421,050.00. Following the completion of the transaction, the insider now directly owns 197,681 shares in the company, valued at approximately $2,378,102.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Y-mAbs Therapeutics news, insider Thomas Gad sold 35,000 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $12.03, for a total value of $421,050.00. Following the completion of the transaction, the insider now owns 197,681 shares of the company’s stock, valued at approximately $2,378,102.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Bo Kruse sold 31,371 shares of the company’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $12.07, for a total value of $378,647.97. Following the sale, the chief financial officer now directly owns 210,877 shares in the company, valued at approximately $2,545,285.39. The disclosure for this sale can be found here. Insiders sold a total of 99,444 shares of company stock worth $1,203,925 over the last ninety days. Company insiders own 21.50% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.